Outlook Therapeutics (OTLK) Receives FDA Acceptance for ONS-5010 BLA Resubmission

The U.S. Food and Drug Administration has accepted Outlook Therapeutics' resubmitted Biologics License Application (BLA) for ONS-5010, a biosimilar candidate for treating wet age-related macular degeneration (AMD), the company announced June 16, 2026. The acceptance initiates a new FDA review cycle for the ophthalmology drug. ONS-5010 is designed as a biosimilar to Lucentis (ranibizumab), an established treatment for wet AMD, a leading cause of vision loss in patients over 60. The FDA's acceptance follows a previous Complete Response Letter, which identified deficiencies requiring correction in the original application. The regulatory milestone represents a critical advancement for Outlook Therapeutics in commercializing the treatment. The FDA will now conduct a comprehensive review of manufacturing processes, clinical efficacy data, and safety profiles. Approval timelines depend on the agency's assessment of the updated submission materials.